- Home
- AVX vs MIST Comparison
AVX vs MIST Comparison
Compare AVX & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AVX | MIST |
|---|---|---|
| Founded | 2017 | 2003 |
| Country | Canada | Canada |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 151.8M | 163.2M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | AVX | MIST |
|---|---|---|
| Price | $1.64 | $2.94 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $6.33 |
| AVG Volume (30 Days) | 309.7K | ★ 4.1M |
| Earning Date | 11-14-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,319,011.00 | N/A |
| Revenue This Year | $530,767.50 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 8001.54 | N/A |
| 52 Week Low | $1.43 | $0.63 |
| 52 Week High | $25.38 | $2.96 |
Technical Indicators
Market Signals| Indicator | AVX | MIST |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 78.26 |
| Support Level | N/A | $2.50 |
| Resistance Level | N/A | $2.73 |
| Average True Range (ATR) | 0.00 | 0.17 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 0.00 | 99.29 |
Price Performance
Historical ComparisonAbout AVX Avax One Technology Ltd. Common Shares
AVAX One Technology Ltd is a public company offering investors regulated access to the Avalanche (AVAX) ecosystem. By integrating the reliability of U.S. capital markets with the growth potential of decentralized finance, it seeks to create a bridge between traditional and digital finance. The company focuses on building a digital-asset treasury, fostering innovation, and investing in decentralized financial technologies that benefit from the Avalanche network.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).